Domingo F. Barber,A. Bartolomé,Ma Carmen Hernández,Juana M. Flores,Clara Redondo,Cristina Fernández-Arias,Montserrat Camps,Thomas Rückle,Matthias Schwarz,S. Sánchez Rodríguez,Carlos Martínez‐A,Dimitrios Balomenos,Christian Rommel,Ana C. Carrera
出处
期刊:Nature Medicine [Springer Nature] 日期:2005-08-28卷期号:11 (9): 933-935被引量:310
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease generated by deregulation of T cell-mediated B-cell activation, which results in glomerulonephritis and renal failure. Disease is treated with immunosuppressants and cytostatic agents that have numerous side effects. Here we examine the use of inhibitors of phosphoinositide 3-kinase (PI3K) gamma, a lipid kinase that regulates inflammation, in the MRL-lpr mouse model of SLE. Treatment reduced glomerulonephritis and prolonged lifespan, suggesting that P13Kgamma may be a useful target in the treatment of chronic inflammation.